Clinical utility of PSMA PET/CT for recurrent prostate cancer

Clinical utility of PET/CT with 18F-FSU-880 for recurrent prostate cancer - PSMA PET for recurrent prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180037

Enrollment

100

Registered

2019-01-29

Start date

2019-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer prostate cancer, PSMA, PET

Interventions

Intravenous administration of the radiopharmaceutical called [18F]-FSU880

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients (Age 20-85 y.o.) with prostate cancer 2. Patients who are suspected of having recurrence due to their increased PSA or diagnostic imaging after surgery for prostate cancer 3. Patients who are determined to be appropriate for this study by participating physicians according to the results of physical examination and blood/urine/physiological function tests. 4. Patients who give us written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients having a severe communication problem. 2. Patients with severe general condition. 3. Patients having severe renal dysfunction (eGFR<30 mL/min/1.73m3) expected to affect the distribution of [18F]FSU-880.. 4. Patients to whom participating physicians judged to be inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
Diagnostic performance of FSU880-PET/CT for recurrent prostate cancer Clinical impact	—

Secondary

Measure	Time frame
Most optimal uptake period for scanning after injection	—

Contacts

Public ContactYoichi Shimizu

Kyoto University Hopistal

yoichis@kuhp.kyoto-u.ac.jp+81-75-751-3760

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026